Rybelsus vs semaglutide injections: what the data says about oral vs injectable GLP-1s

What did @performingoem actually say?

Honestly, it's hard to tell. The transcript recovered from this video is largely incoherent, referencing something about "the former robo Grande Rusnica" and "seventeen years" with no clear medical claim attached. The caption promises a comparison between Rybelsus (oral semaglutide) and injectable semaglutide, specifically "the difference you don't see." But the spoken content doesn't deliver that comparison in any intelligible way.

What we can work with is the implied premise of the video: that there is a meaningful, hidden difference between oral and injectable semaglutide that most people miss. That's actually a legitimate topic worth examining, even if this particular video doesn't examine it coherently.

Does the science back up the oral vs. injectable distinction?

Yes, and it's more significant than most people realize. The short answer is that oral semaglutide (Rybelsus) and injectable semaglutide (Ozempic, Wegovy) are not interchangeable, and the difference goes well beyond needle phobia.

Oral semaglutide has dramatically lower bioavailability. A 2019 study by Pratley et al. published in The Lancet Diabetes and Endocrinology (the PIONEER 1 trial) showed that Rybelsus at 14 mg daily produced meaningful HbA1c reductions, but the oral formulation requires co-administration with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) to even survive the stomach. Absorption is estimated at roughly 1% without this carrier mechanism. Compare that to subcutaneous injection, where bioavailability is approximately 89% (Buckley et al., 2018, Clinical Pharmacokinetics). That's not a minor footnote. It changes how the drug behaves, when it peaks, and how consistent its effects are day to day.

What did they get wrong, or right?

The caption premise is right. There genuinely is a difference most people overlook. But the video as transcribed never actually explains what that difference is, which makes it more of a teaser than a fact-based comparison.

What the video appears to miss, or at least fails to articulate, is the clinical weight-loss gap between formulations. The STEP and PIONEER trial programs tell different stories. Injectable semaglutide at 2.4 mg weekly (Wegovy) produced average body weight reductions of around 14.9% over 68 weeks in the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine). Oral semaglutide at 50 mg daily, the highest dose studied, produced approximately 15.1% weight reduction in the OASIS 1 trial (Knop et al., 2023, The Lancet), which is roughly comparable but requires a much larger dose and strict fasting protocols to hit those numbers. The practical compliance burden is very different.

• Rybelsus must be taken on an empty stomach with no more than 4 oz of plain water, then the patient must wait 30 minutes before eating or drinking anything else.
• Missing that window meaningfully reduces absorption.
• Injections don't carry those restrictions.

What should you actually know?

If you're considering oral versus injectable semaglutide, the choice isn't just about avoiding needles. Absorption variability with oral semaglutide is real and clinically relevant. Food, coffee, even some medications can blunt how much of the drug actually reaches your bloodstream.

A 2021 pharmacokinetic analysis by Davies et al. in Diabetes, Obesity and Metabolism found that co-administration of oral semaglutide with a small meal reduced exposure by approximately 50% compared to fasted administration. That's a significant reduction based on a single behavioral slip.

Injectable semaglutide delivers more predictable plasma concentrations week to week. For patients managing type 2 diabetes where consistency matters, that predictability has real clinical value. For weight management, patient adherence to dosing instructions may ultimately determine which formulation works better for a given individual, not the molecule itself.

Neither formulation cures diabetes or obesity. Both require lifestyle support to produce meaningful, sustained results. Anyone presenting this as a simple swap is oversimplifying the pharmacology.